Core Insights - ClearPoint Neuro's medical device is significant in UniQure's strategy to combat Huntington's disease [1] Company Summary - ClearPoint Neuro provides a medical device that is integral to the treatment efforts for Huntington's disease by UniQure [1] - UniQure is leveraging ClearPoint Neuro's technology to enhance its capabilities in addressing Huntington's disease [1]

Group 1 - The article discusses the investment analysis service provided by Biotech Analysis Central, which focuses on pharmaceutical companies and offers a subscription model for in-depth research [1][2] - The service includes a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis tools to assist healthcare investors [2] - A previous article on uniQure N.V. highlighted the progress of AMT-130 for Huntington's Disease, with an upcoming FDA meeting scheduled for Q2 2025 [2]

Group 1 - The article discusses the investment analysis service provided by Biotech Analysis Central, which focuses on pharmaceutical companies and offers a subscription model for in-depth research [1][2]. - The service includes a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis tools to assist healthcare investors [2]. - A previous article on uniQure N.V. highlighted the progress of AMT-130 for Huntington's Disease, with an upcoming FDA meeting scheduled for Q2 2025 [2].

Skip to Main Content This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. These Stocks Moved the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More By Joe Woelfel, Elsa Ohlen, Mackenzie Tatananni and Connor Smith Share Resize Reprints Continue ...

Core Viewpoint - Orsted has resumed work on a U.S. offshore wind project following a federal judge's ruling that allows construction to restart amid ongoing legal challenges from the Trump administration [1] Group 1 - Orsted is a key player in the offshore wind industry, and the resumption of construction indicates a positive development for renewable energy projects in the U.S. [1] - The federal judge's ruling is significant as it provides a legal pathway for Orsted to continue its operations despite the ongoing legal case [1]

Core Viewpoint - uniQure N.V. has initiated a $200 million underwritten public offering of its ordinary shares and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the total shares sold [1][2]. Company Overview - uniQure is a leading gene therapy company focused on developing transformative therapies for patients with severe medical needs, including gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease [5]. - The company has achieved significant milestones in genomic medicine, particularly with its gene therapy for hemophilia B, which is based on over a decade of research and clinical development [5]. Offering Details - The public offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1]. - The offering is being conducted under an automatically effective shelf registration statement filed with the SEC [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website [3]. Underwriters - The bookrunning managers for the offering include Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities [2].

Uniqure (QURE) stock soared nearly 300% on Wednesday after the Dutch biotechnology company announced a major breakthrough in Huntington’s disease. Investors are cheering QURE shares this morning because the Nasdaq-listed firm has secured new financing worth $175 million from Hercules Capital as well. More News from Barchart QURE stock is now trading roughly 460% above its year-to-date low in early April. www.barchart.com Why Did the Clinical Data Light a Fire Under QURE Stock? Uniqure shares are rall ...

Company Highlights - Cidara Therapeutics Inc. (CDTX) reached a 52-week high of $87.19 as it advances its development plan for CD388, a non-vaccine preventive treatment for seasonal influenza, with enrollment in a Phase 3 study expected to start by September 2025 targeting 6,000 participants [1] - Maze Therapeutics Inc. (MAZE) saw its stock rise to a 52-week high of $27.09 following positive Phase 1 clinical results for MZE782, an oral therapy for Phenylketonuria and chronic kidney disease, with plans to enter Phase 2 studies in 2026 [3][4] - Medpace Holdings Inc. (MEDP) is set to report Q3 2025 financial results on October 22, 2025, and has raised its full-year guidance twice, indicating strong operational momentum, with the stock hitting a 52-week high of $506.55 [5][6] - Monopar Therapeutics Inc. (MNPR) rebounded from potential Nasdaq delisting to a 52-week high of $73.75, planning to seek approval for ALXN1840 for Wilson disease in early 2026, supported by long-term clinical data [7][8] - Prenetics Global Limited (PRE) projects 2025 revenue between $85 million and $100 million, a significant increase from $30.6 million in 2024, with its new wellness brand IM8 Health on track for $100 million in annual recurring revenue [9][10] - Protagonist Therapeutics Inc. (PTGX) is nearing a major milestone with Icotrokinra for psoriasis, having submitted a regulatory application to the FDA and EMA in July 2025, with the stock reaching a 52-week high of $66.70 [11][12] - uniQure N.V. (QURE) announced positive results from its Phase I/II study of AMT-130 for Huntington's disease, planning to submit a Biologics License Application in Q1 2026, with the stock soaring over 200% to a 52-week high of $51.21 [13][14] - Rezolute Inc. (RZLT) surged to a 52-week high of $9.02 ahead of topline results from its pivotal Phase III trial for hypoglycemia treatment, expected in December [15][16] - United Therapeutics Corp. (UTHR) reached a 52-week high of $442.01 as anticipation builds for data from the TETON-2 study of nebulized Tyvaso in idiopathic pulmonary fibrosis, with positive results reported earlier [17][18]

Market Overview - U.S. stocks experienced a decline, with the Nasdaq Composite falling over 100 points on Wednesday. The Dow decreased by 0.35% to 46,129.26, the NASDAQ fell by 0.47% to 22,468.39, and the S&P 500 dropped by 0.40% to 6,630.54 [1] - Energy shares saw an increase of 1.9% on Wednesday, while materials stocks fell by 1.5% on Tuesday [1] Commodity Market - In commodity trading, oil prices rose by 2.5% to $64.97, while gold prices decreased by 1.3% to $3,767.30. Silver fell by 1.1% to $44.105, and copper increased by 3.8% to $4.8220 [4] European Market - European shares were mostly higher, with the eurozone's STOXX 600 rising by 0.01%, Spain's IBEX 35 Index increasing by 0.2%, London's FTSE 100 up by 0.29%, Germany's DAX 40 rising by 0.23%, and France's CAC 40 falling by 0.57% [5] Asian Market - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng surging by 1.37%, China's Shanghai Composite rising by 0.83%, while India's BSE Sensex fell by 0.47% [6] Company News - uniQure N.V. shares surged by 235% to $45.79 after announcing a $175 million non-dilutive senior secured term loan facility with Hercules Capital [8] - SHF Holdings, Inc. saw its shares increase by 120% to $7.18 following a $150 million common stock purchase agreement with CREO [8] - Lithium Americas Corp. shares rose by 97% to $6.05 after reports that Trump officials are seeking an equity stake in the company as part of a $2.26 billion loan renegotiation for the Thacker Pass lithium project [8] - WORK Medical Technology Group LTD shares plummeted by 88% to $0.1081 after partnering with Hong Kong Web3.0 Standardization Association for blockchain and RWA innovations [8] - Firefly Aerospace Inc. shares decreased by 33% to $0.7142, and Zhengye Biotechnology Holding Limited shares fell by 28% to $5.01 [8] Economic Indicators - Sales of new single-family homes in the U.S. increased by 20.5% from the previous month to an annualized rate of 800,000 units in August [10] - Building permits in the U.S. declined by 2.3% to an annualized rate of 1.330 million in August [10] - The volume of mortgage applications rose by 0.6% from the previous week in the week ending September 19 [10]

Market Overview - U.S. equities experienced a pullback on September 24, 2025, after a multi-day rally, with major indexes drifting lower as investors took profits and digested comments from Federal Reserve Chair Jerome Powell regarding elevated asset valuations [1][3] - The S&P 500 was down 0.3% to close at 6,656.92, following a 0.6% decline on Tuesday, while the Nasdaq Composite fell 0.4% to 22,573.47, and the Dow Jones Industrial Average decreased by 0.2% to 46,292.78 [2] Sector Performance - The Energy sector rose by 2% on September 24, supported by a 2% increase in West Texas Intermediate crude oil futures, which reached $64.75 per barrel [4] - The Information Technology and Materials sectors were among the worst performers, both down approximately 1% in afternoon trading, reflecting a broader pullback in growth-oriented assets [5] Company News - Micron Technology (MU) saw a decline of roughly 4% despite reporting record quarterly sales, attributed to profit-taking after a substantial year-to-date gain of 97.7% [13] - Alibaba (BABA) shares surged nearly 9% after announcing plans to increase its AI infrastructure budget beyond $53 billion, indicating strong investor interest in AI investments [13] - Freeport-McMoRan (FCX) plummeted over 10% after lowering its third-quarter sales outlook for copper and gold, alongside a tragic incident in Indonesia [13] - Boeing Co. (BA) gained 2% following an $8 billion agreement to deliver 22, 787 Dreamliners to Uzbekistan Airways [13] - uniQure (QURE) experienced a remarkable surge of 241% after releasing positive results from its Huntington's gene therapy [13] - Nike (NKE) shares are trading just under $71, with analysts anticipating significant price increases ahead of its upcoming quarterly update [13] - Adobe (ADBE) shares fell after a downgrade from Morgan Stanley to 'Equal-Weight' [13] Upcoming Market Catalysts - Investors are monitoring the upcoming release of the U.S. core Personal Consumption Expenditures (PCE) price index on September 26, which is a key inflation gauge [7] - Flash Purchasing Managers' Index (PMI) surveys and revised U.S. GDP numbers are also on the economic calendar, providing insights into economic growth and inflation trends [7][9]